Ribavirin

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide <ref>DOI: 10.1093/jac/dki405 </ref> (from "Gish" in general info)
+
1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide <ref>DOI: 10.1093/jac/dki405 </ref>
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''>
<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''>
This is a default text for your page '''Ribavirin'''. Click above on '''edit this page''' to modify. Be careful with the &lt; and &gt; signs.
This is a default text for your page '''Ribavirin'''. Click above on '''edit this page''' to modify. Be careful with the &lt; and &gt; signs.
Line 5: Line 5:
== Overview ==
== Overview ==
-
Ribavirin was first synthesized in 1970 by ICN Pharmaceuticals (now “Valent International Pharmaceuticals”). In 1986, its first major use was the treatment of RSV (respiratory syncitial virus) infections in pediatric patients. Since its FDA approval in 1998, it has primarily been used as a component in treating Hepatitis C. The treatment was modified and approved in 2002 by the FDA by combining it with interferon alfa2b. (from “Gish” in general info)
+
Ribavirin was first synthesized in 1970 by ICN Pharmaceuticals (now “Valent International Pharmaceuticals”) <ref>DOI: 10.1093/jac/dki405 </ref>. In 1986, its first major use was the treatment of RSV (respiratory syncitial virus) infections in pediatric patients, but since its FDA approval in 1998, it has primarily been used as a component in treating Hepatitis C.<ref>DOI: 10.1093/jac/dki405 </ref> The treatment was modified and approved in 2002 by the FDA by combining it with interferon alfa2b <ref>DOI: 10.1093/jac/dki405 </ref>.
== Structure & Function ==
== Structure & Function ==

Revision as of 02:16, 16 November 2016

1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide [1]

Caption for this structure

Drag the structure with the mouse to rotate

References

  • 1. Gish, R. G. (2005, November 17). Treating HCV with ribavirin analogue and ribavirin-like molecules. Journal of Antimicrobial Chemotherapy, 1-6. doi:10.1093/jac/dki405

3. Chung, R.T., Gale, M.J., Polyak, S.J., Lemon, S.M., Liang, T.J., & Hoofnagle, J.H. (2008). Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology, 47 (1), 306-320. doi: 10.1002/hep.22070 4. National Heart, Lung and Blood Institute. (2016, September 26). Pneumonia. Retrieved from https://www.nhlbi.nih.gov/health/health-topics/topics/pnu

Personal tools